Italia markets closed

Psyence Group Inc. (PSYG.CN)

Canadian Sec - Canadian Sec Prezzo in tempo reale. Valuta in CAD.
Aggiungi a watchlist
0,01000,0000 (0,00%)
Alla chiusura: 01:48PM EDT
Schermo intero
Chiusura precedente0,0100
Aperto0,0000
Denaro0,0000 x N/D
Domanda0,0000 x N/D
Min-Max giorno0,0100 - 0,0100
Intervallo di 52 settimane0,0100 - 0,1500
Volume699
Media Volume91.531
Capitalizzazione1,374M
Beta (mensile su 5 anni)0,39
Rapporto PE (ttm)N/D
EPS (ttm)-0,0500
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Psyence Group Announces Closing of Private Placement & Conclusion of Loan Agreement

    TORONTO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG | OTCQB:PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it has issued 1,056,441 common shares at a price of CAD$0.12 per common share for gross proceeds of CAD$126,773. In connection with this issuance, the Company also issued 17,691 common shares a price of CAD$0.12 per common share as payment of a finder's f

  • GlobeNewswire

    Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement

    VANCOUVER, British Columbia, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a clinical-stage life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being (“Psyence”), and Newcourt Acquisition Corp (“Newcourt”) (Nasdaq: NCAC), a special purpose acquisition company (“SPAC”) today announced the entry into an amended and restated business combination agreement (the “Amended and Restated Business Combination Agreement”),

  • GlobeNewswire

    Psyence Group Corporate Update

    Highlights: Drug development, Phase IIb clinical trial advanced planning underway in AustraliaPsyence granted worldwide licensing agreement to commercialize Filament’s PEX010 (25 mg) in palliative care with exclusivity in key marketsSuccessful completion of exports of medical grade psilocybin mushrooms to three key global marketsExtraction capabilities enhanced at Psyence’s production facilityChristopher Bull appointed to the board of directors to drive Psyence’s intellectual property strategy T